-
公开(公告)号：US4496658A
公开(公告)日：1985-01-29
申请号：US311327
申请日：1981-10-14
Applicant: Koichi Kondo , Susumu Iwasa , Isamu Yoshida
Inventor： Koichi Kondo , Susumu Iwasa , Isamu Yoshida
IPC: C07K14/59 , C07K16/26 , C12N9/96 , G01N33/531 , G01N33/535 , G01N33/543 , G01N33/76 , G01N33/54 , G01N33/56 , G01N33/58
CPC classification number: C07K14/59 , C07K16/26 , C12N9/96 , G01N33/531 , G01N33/535 , G01N33/54306 , G01N33/76 , Y10S435/975 , Y10S436/80 , Y10S436/804 , Y10S436/808 , Y10S436/813 , Y10S436/814 , Y10S436/819 , Y10S930/11 , Y10S930/28
Abstract: In a method for immunochemical assay of human chorionic gonadotropin involving use of an antibody immobilized on a carrier, an antigen and an antibody to which a labeling agent has been attached, when the antibody supported on the carrier and the antibody coupled to a labeling agent are different antibodies which are not overlapping in antigen-determining site and one of said different antibodies is specifically reactive to human chorionic gonadotropin, a high reproducibility of the result of the immunochemical assay is obtained.
Abstract translation: 在涉及使用固定在载体上的抗体，附着有标记试剂的抗原和抗体的人绒毛膜促性腺激素的免疫化学测定方法中，当载体上载有抗体和与标记试剂偶联的抗体时， 在抗原决定部位和所述不同抗体之一中不重叠的不同抗体与人绒毛膜促性腺激素特异性反应，获得了免疫化学测定结果的高再现性。
-
公开(公告)号：US20240327487A1
公开(公告)日：2024-10-03
申请号：US18605381
申请日：2024-03-14
Applicant: Ferring International Center S.A.
Inventor： Ian COTTINGHAM , Daniel PLAKSIN , Richard Boyd WHITE
Abstract: Preparations including recombinant FSH (rFSH).
-
公开(公告)号：US20240228571A9
公开(公告)日：2024-07-11
申请号：US18375407
申请日：2023-09-29
Inventor： Marcelo Dias BARUFFI , Camillo del Cistia ANDRADE , Rubens Eduardo da SILVA , Robinson Antonio Martins de OLIVEIRA , Daniel Roberto CALLEJON
Abstract: Disclosed is a method for producing hybrid or non-hybrid recombinant glycoprotein hormones, for example the recombinant equine chorionic gonadotropin (r-eCG), the hybrid recombinant chorionic gonadotropin, the recombinant thyroid-stimulating hormone (r-TSH), the recombinant luteinizing hormone (r-LH), the luteinizing hormone and the recombinant follicle-stimulating hormone (r-FSH). In addition, the present disclosure relates to the recombinant glycoprotein hormones comprising the equine α and β subunits, inter alia, the α subunit of mammals and equine β subunit, where the two subunits are fused in a simple chain, and chain-modifying agents, which hormones are easier to purify, more homogeneous, easier to produce on an industrial scale without using animals, in comparison with the wild glycoprotein hormone. The hormones are useful for inducing animal reproduction, ovulation induction, superovulation induction, follicle growth, estrus induction, anoestrus reversal, puberty induction in animals, both with and without commercial interest.
-
公开(公告)号：US11913043B2
公开(公告)日：2024-02-27
申请号：US17519545
申请日：2021-11-04
Applicant: Research Development Foundation
Inventor： Xinjian Lin , Xiying Shang , Stephen B. Howell
CPC classification number: C12N9/6467 , A61K47/65 , A61K47/6889 , C07K14/43504 , C07K14/59 , C12N9/52 , C12N9/6424 , C12N9/96 , C12Y304/21079 , C12Y304/2207 , C12Y304/22007 , A61K48/00 , C07K2319/00 , C07K2319/21 , C07K2319/33 , C07K2319/40 , C07K2319/55 , C07K2319/70 , C07K2319/74 , C07K2319/90
Abstract: The invention is directed to cell-targeted cytotoxic agents, including sortase serine protease constructs. Methods for targeted cell killing for treatment of proliferative diseases, for example, cancer, are provided. Exemplary embodiments comprise an R-spondin ligand for targeting the cytotoxic agents to effect the cell killing.
-
公开(公告)号：US20230416325A1
公开(公告)日：2023-12-28
申请号：US18323124
申请日：2023-05-24
Inventor： Yong Sung Kim , Keunok Jung , Ji Hee Ha , Dong Ki Choi , Hye Ji Choi , Ye Jin Kim
CPC classification number: C07K14/5434 , A61K38/208 , C07K14/59 , C07K14/54 , A61K38/00
Abstract: The present invention relates to a heterodimeric Fc-fused protein comprising a first Fc region and a second Fc region of an immunoglobulin Fc pair and a physiologically active protein composed of two or more different subunits, wherein one or more subunits of the physiologically active protein are linked separately to one or more ends of the N-terminus or C-terminus of the first Fc region and/or the second Fc region, and CH3 domains of the first Fc region and the second Fc region are mutated so as to promote the heterodimeric Fc formation. Moreover, the present invention relates to a pharmaceutical composition comprising the heterodimeric Fc-fused protein.
-
公开(公告)号：US20230374095A1
公开(公告)日：2023-11-23
申请号：US18309982
申请日：2023-05-01
Applicant: Box, Inc.
Inventor： Rohit Bakshi , Daniel Wayne Morkovine , Faizan N. Buzdar
IPC: C07K14/59 , C07K14/505 , C07K14/555 , C07K14/575 , C07K14/61 , C12N9/64 , C12N15/85 , G06Q10/0633 , G06Q10/0637 , G06Q10/0639 , G06Q30/0201
CPC classification number: C07K14/59 , C07K14/505 , C07K14/555 , C07K14/575 , C07K14/61 , C12N9/6437 , C12N9/644 , C12N15/85 , G06Q10/0633 , G06Q10/0637 , G06Q10/06393 , G06Q30/0201 , A61K38/00
Abstract: Methods, systems and computer program products for shared content management systems that provide performance analytics pertaining to a project. Embodiments include establishing one or more network communication links between a content management system that manages a plurality of shared content objects and a plurality of applications that cause modifications to the shared content objects in accordance with workflows of the project. Iteraction events that correspond to modifications over the shared content objects are recorded such that interaction events associated with the plurality of applications are selected based at least in part on attributes associated with the interaction events. Relationships between the recorded interaction events such as time durations between certain of the interaction events are calculated. Project performance measurements are generated based on the calculations and/or based on other relationships between the interaction events. The calculations may span across many different applications and/or many different departments and/or many different enterprises.
-
公开(公告)号：US20230000927A1
公开(公告)日：2023-01-05
申请号：US17941352
申请日：2022-09-09
Applicant: JangoBio, LLC
Inventor： Craig S. Atwood , Sivan Vadakkadath Meethal
IPC: A61K35/545 , A61K35/52 , A61K35/55 , A61P5/24 , A61P5/06 , C07K14/59 , A61K35/54 , A61K35/15 , A61K31/568 , A61K31/566 , A61K31/57
Abstract: Methods are described for differentiating stem and post-natal cells into sex hormone-producing cells that can be administered to a patient autologously or allogeneically in order to maintain in balance, or rebalance, their hypothalamic-pituitary-gonadal (HPG) axis.
-
公开(公告)号：US20220281940A1
公开(公告)日：2022-09-08
申请号：US17662312
申请日：2022-05-06
Inventor： T. Rajendra Kumar
Abstract: The present inventive concept is related to a modified follicle-stimulating hormone (FSH), in particular, a hypo-glycosylated form of FSH, as well as compositions and formulations including, nucleic acids encoding, cell lines expressing, and methods of using the hypo-glycosylated FSH as disclosed herein. These methods of use include methods of treating infertility, methods of inducing follicle growth and/or maturation, methods of inducing oocyte/egg growth and/or maturation, methods of stimulating sex steroid secretion, methods of treating or preventing bone density loss, and methods of treating or preventing fatty tissue accumulation.
-
99.发明授权
公开(公告)号：US11299527B2
公开(公告)日：2022-04-12
申请号：US16609543
申请日：2017-11-01
Applicant: BEIJING VJT BIO CO., LTD.
Inventor： Haoshu Luo , Lei Shi , Guo Han
Abstract: Two long-acting recombinant porcine FSH (follicle-stimulating hormone) fusion proteins, comprising pFSH-Fc-1 and pFSH-Fc-2. α subunit/β subunit is directly or indirectly fused on a Fc fragment by means of a linking component; the β subunit/α subunit is combined with the α subunit/β subunit by means of a Van der Waals force or the linking component. The porcine FSH fusion proteins can be prepared by an eukaryotic expression system based on a gene engineering technology. The two porcine FSH fusion proteins have a good medicinal effect and have a longer half-life period as compared with that of a natural porcine FSH; the two porcine FSH fusion proteins do not generate an undesirable effect on animals and can replace pregnant mare serum gonadotropin (PMSG) to be used in animal breeding production. The two porcine FSH fusion proteins can be used for preparation of medicines in the field of animal breeding.
-
公开(公告)号：US20220016225A1
公开(公告)日：2022-01-20
申请号：US16933157
申请日：2020-07-20
Inventor： Lowell A. Miller , Jack C. Rhyan
Abstract: The immune response of an animal to a target immunogen may be enhanced by use of an adjuvant which includes low concentrations of killed cells of Mycobacterium avium subspecies avium in combination with mineral oil. The adjuvant may be used in vaccine compositions for the immunization of an animal against any target immunogen and is particularly preferred for use with immunocontraceptive vaccines such as GnRH immunocontraceptive vaccines conjugated with a Blue carrier protein.
